ECMOHO Limited Announces Proposed Underwritten Public Offering of American Depositary Shares

ECMOHO Limited Announces Proposed Underwritten Public Offering of American Depositary Shares




ECMOHO Limited Announces Proposed Underwritten Public Offering of American Depositary Shares

SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) — ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the health and wellness market in China, today announced that it intends to offer American depositary shares, or ADSs, each representing four of its Class A ordinary shares, for sale in an underwritten public offering. The Company intends to use the net proceeds from this offering for general corporate and working capital needs. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Aegis Capital Corp. is acting as the sole book-running manager for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333-257200) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on July 6, 2021. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus, when available, and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ECMOHO Ltd.

ECMOHO is a leading integrated solutions provider in the health and wellness market in China, which curates and sells the best global brands and quality products to Chinese health-conscious consumers. Leveraging its technology, network and expertise in marketing and distribution, ECMOHO connects families with advanced health supplements, nutrition and food items, personal care products, household healthcare equipment and other wellness products. Through over ten years of operation, ECMOHO has established an ecosystem of trusted products and relationships to provide customized solutions which promote health regeneration, impart therapeutic benefits, and increase longevity to devoted consumers to sustain health. For more information, please visit http://ir.ecmoho.com/.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “going forward,” “outlook” and similar statements. For example, the Company’s statements about its ability to complete the offering and its intended use of proceeds are forward-looking statements and are inherently uncertain. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, such as the significant volatility and disruption caused by the COVID-19 pandemic, the Company’s expected growth of the online retail industry in China, the Company’s expectations regarding demand for and market acceptance of its products and services, the Company’s expectations regarding its relationships with its brand partners and e-commerce channels, and the level of consumer economic activity in China, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For investor and media inquiries, please contact:

ECMOHO Ltd.
Investor Relations
Email: IR@ecmoho.com

Investor relations agency contact:

William Tu / Scott Powell
Skyline Corporate Communications Group, LLC
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: (646) 893-5835

Email: wtu@skylineccg.com

Small Pharma Reports First Fiscal Quarter 2021 Highlights

Small Pharma Reports First Fiscal Quarter 2021 Highlights




Small Pharma Reports First Fiscal Quarter 2021 Highlights

Successful completion of listing on TSX Venture Exchange

$58 million financing enables potential rapid advancement of Small Pharma’s patent portfolio

LONDON, United Kingdom, July 30, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT”) therapies, has today published its first quarter results for the three months ended May 31, 2021. A full copy of the results can be found under the Company’s profile on SEDAR at www.sedar.com. Unless otherwise indicated, all currency references are to Canadian dollars.

Operational Highlights (including post-period events):

  • Strong progress in Phase I/IIa clinical trial for lead product, SPL026, DMT-assisted therapy for the treatment of depression
    • Completion of fourth cohort in the Phase I component of the study
    • Acceleration of Phase IIa with addition of second clinical trial site
    • Topline data readout of Phase IIa anticipated H1 2022
  • Preparation underway for Phase IIb DMT-assisted therapy clinical trial, anticipated to commence in H2 2022
    • Launch of psychotherapy training program ahead of Phase II clinical trials
    • Positive discussions with UK Medicines and Healthcare products Regulatory Agency (“MHRA”) on Phase IIb clinical trial design
  • Advancement of other pipeline candidates towards clinical studies including:
    • SPL028, prolonged duration DMT
      • Anticipate completion of pre-clinical studies by year end
      • Start of Phase I/IIa anticipated to commence H1 2022
  • Grant of UK patent covering composition of matter protection on a range of novel tryptamines

Financial Highlights:

  • Completion of the Company’s “go-public” transaction, by way of a reverse takeover of Unilock Capital Corp. (the “Reverse Takeover”), on the TSX Venture Exchange (the “TSXV”) under the ticker symbol “DMT”
  • Successful financing of $58 million
  • Loss for the period of $5.2 million (May 31, 2020: $0.4 million), an increase due primarily to commencement of clinical trials
  • Operating expenses increased to $3.2 million (May 31, 2020: $0.4 million) reflecting the increased R&D costs, advertising and promotion costs, together with professional fees, salaries and wages
  • $52.8 million cash as of May 31, 2021

Peter Rands, Chief Executive Officer of Small Pharma, said: “We have made considerable progress leading the first DMT clinical trial under regulatory approval. Major progress across our portfolio of DMT-assisted therapies during the quarter includes the initiation of our Phase I/IIa clinical trial for the treatment of depression, preparation of the Phase IIb clinical trial, including positive discussions with MHRA on trial design. This work has been supported by our successful $58 million financing and subsequent listing on the TSXV. The continued support of our investors and a stable financial base is expected to assist us with our objective of rapidly progressing and building out our patent portfolio in the coming year, creating a strong foundation for advancing DMT-based therapies for mental health conditions.”

Overview

Psychedelics have been shown to have therapeutic benefits in disorders such as depression, anxiety, substance abuse and post-traumatic stress disorder. These so-called “internalizing disorders” are characterized by debilitating flows of recurring negative thoughts. Clinical research suggests that DMT will disrupt the neuronal pathways underlying these negative thought processes and, by doing so, may facilitate the clinical benefits of therapy given in combination with DMT. DMT-assisted therapy targets the root cause of depression and other “internalizing” conditions and has the potential to provide a treatment with rapid onset and a long duration of antidepressant effect following treatment.

In March 2021, Small Pharma successfully raised $58 million from new and existing securityholders, leading to the completion of the Reverse Takeover and listing on the TSXV in May 2021. With a robust financial base, the Company has initiated a number of steps to accelerate development of its patent portfolio.

Strong progress in Phase I/IIa clinical trial for lead product, SPL026, for the treatment of depression

Small Pharma has initiated a blinded, two-part Phase I/IIa clinical trial. Phase I of the study aims to demonstrate the safety, tolerability, pharmacokinetics and pharmacodynamics of different dose levels of SPL026, a DMT fumarate, in psychedelic-naïve subjects when compared to placebo. Phase IIa, the patient proof of concept, will assess the efficacy, safety and tolerability of one versus two doses of SPL026 versus a placebo in combination with psychotherapy, in patients with major depressive disorder. Efficacy will be assessed using the Montgomery-Asberg Depression Rating scale to measure the severity of depressive episodes.

Completion of fourth cohort of SPL026 therapy
Small Pharma has successfully completed the administration of SPL026, DMT-assisted therapy to 32 psychedelic-naive healthy subjects in the Phase I component of the trial. The study will provide data to support dose selection for the Phase IIa proof of concept component of the clinical trial, which is on track to commence in Q3 2021.

Acceleration of Phase IIa with addition of second clinical trial site
In June 2021, Small Pharma secured an additional clinical trial site with MAC Clinical Research at Prescott, Liverpool in the UK, increasing the total number of patients in its Phase IIa trial to 42. As a result of this appointment, timelines for the Phase I/IIa clinical trial are expected to accelerate with anticipated top-line results brought forward from the end of 2022 to the first half of 2022.

Preparations underway for Phase II DMT-assisted therapy clinical trials

Launch of psychotherapy training program ahead of Phase II clinical trials
In July 2021, Small Pharma launched its DMT-assisted therapy training program to educate therapists on the process required to support treatment delivery of Small Pharma’s DMT-assisted therapy clinical trials. The initial training program was successfully completed at the University of Oxford and will help set the foundations for the effective delivery of this treatment.

Positive discussions with MHRA on Phase IIb clinical trial protocol
Small Pharma had positive discussions with UK regulators on the preliminary protocol for the Company’s Phase IIb clinical trial, anticipated to commence in the second half of 2022. The MHRA endorsed minimal additional preclinical safety studies based on the additional human exposure data being obtained in the Phase I/IIa clinical trial, which provides an expedited nonclinical path to the start of the Phase IIb study. In addition, the MHRA commented positively regarding the design of the Phase IIb study noting thoroughness of the clinical design including patient population, the inclusion/exclusion criteria and the overall study design.

Advancement of pipeline candidates towards clinical studies
Small Pharma has progressed preclinical studies for its pipeline of novel DMT analogues, including in vivo pharmacokinetic studies and behavioral pharmacology studies and remains on track to select the next candidates to progress towards clinical trials in 2022.

Grant of UK patent
In July 2021, Small Pharma received granted status under patent number GB2585978 for its UK patent application GB2008303.6. The UK patent office has determined the novelty of exploiting the effects of deuterium modification of DMT and additional tryptamines to control the duration of its psychological effects. This patent covers composition of matter protection on a range of novel tryptamines that delivers an extended psychedelic experience for use in protocols for treating depression. Small Pharma is using this technology to create novel DMT analogues, including SPL028, a second generation psychedelic substance that may provide flexibility and expand administration routes. The Company is building a robust IP portfolio with two patents granted and 36 patent applications pending across its psychedelic and non-psychedelic portfolio.

Options Grants
The Company announces that the board of directors of the Company has granted options to purchase up to an aggregate of 1,090,000 common shares to certain directors and officers of the Company pursuant to the Company’s stock option plan. Each option is exercisable for one common share at a price equal to the greater of (i) $0.49 per share; and (ii) the closing price of the common shares on Tuesday, August 3, 2021, being the first trading day after the release of the Company’s financial results. The options are exercisable for a period of ten years and are subject to certain vesting requirements.

Outlook
Small Pharma has made considerable progress across its patent portfolio of DMT-assisted therapies with the initiation of its Phase I/IIa clinical trial for the treatment of depression and preparation of the Phase IIb clinical trial. This work has been supported by the Company’s successful $58 million financing and subsequent listing on the TSXV. The continued support of Small Pharma’s investors and a stable financial base is enabling the Company to rapidly progress and is expected to accelerate the build out of its patent portfolio in the coming year, creating a strong foundation to advance treatment to address the unmet need in mental health conditions.

About Small Pharma
Small Pharma is a neuropharmaceutical company specialized in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021. This program includes a Phase I/IIa trial on its lead candidate, SPL026, alongside development of a robust pipeline of proprietary preclinical assets.

About DMT
DMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London.

For further information contact: 

Small Pharma Inc.
Peter Rands
Chief Executive Officer
Email: ir@smallpharma.co.uk
Tel: +44 (0)2071 129118

Investor Relations Contact
Eric Ribner
LifeSci Advisors, LLC
Email: eric@lifesciadvisors.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this news release include statements regarding the current and future status of the Company’s patent applications, rapid advancement and build-out of the Company’s patent portfolio, the Company’s success in launching a clinical program into DMT-assisted therapy, acceleration of the development of the Company’s patent portfolio, data to support dose selection for the Phase IIa proof of concept component of the clinical trial of SPL026, the impact of the Company’s training program, the outcome of any discussions with regulators including but not limited to the MHRA, the Company’s development of a robust pipeline of proprietary preclinical assets, the potential of DMT to transform the lives of patients suffering with depression, the Company’s training program and the results thereof, the completion of the Company’s pre-clinical studies and the commencement and results of the Company’s Phase IIa and Phase IIb clinical trials. In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting the Company’s business and results of operations; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

Small Pharma makes no medical, treatment or health benefit claims about its proposed products. The MHRA or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next generation psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved research. There is no assurance that such DMT-assisted therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharma’s performance and operations.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. Small Pharma’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The TSXV has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 10 individuals hired by Sarepta in July 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received, in the aggregate, options to purchase 20,450 shares of Sarepta’s common stock, and in the aggregate 10,400 restricted stock units (“RSUs”). The options have an exercise price of $67.78 per share, which is equal to the closing price of Sarepta’s common stock on July 30, 2021 (the “Grant Date”). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.

One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

Healthy Extracts Launches New Corporate Brand Awareness Campaign Following Recent Launch of Breakthrough Nutraceutical Formulation, Ultimate Brain Nutrients ACTIVATE™

Healthy Extracts Launches New Corporate Brand Awareness Campaign Following Recent Launch of Breakthrough Nutraceutical Formulation, Ultimate Brain Nutrients ACTIVATE™




Healthy Extracts Launches New Corporate Brand Awareness Campaign Following Recent Launch of Breakthrough Nutraceutical Formulation, Ultimate Brain Nutrients ACTIVATE™

LAS VEGAS, July 30, 2021 (GLOBE NEWSWIRE) — Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain health, has launched a new company and brand awareness campaign with InvestingChannel, an online financial media platform.

The InvestingChannel audience is largely unique among the top financial portals and major financial publishers, with monthly unique views totaling more than 25 million. Its network reaches more than 18 million retail investors and 2.2 million financial professionals across North America, including financial advisors, insurance professionals and institutional investors.

The new campaign is designed to raise awareness of Healthy Extracts’ plant-based, clinically proven heart, immune and brain health formulations, and its opportunities for growth in the multibillion-dollar natural health supplement markets.

The program will raise awareness by building stronger brand recognition through data-driven solutions, including newsletters with up to 280,000 readers, such as Insider Monkey, Activa Traders and Eagle Financial. It may also include native advertisement placements such as homepage posts and article postings on more than 50 sites, including FinViz, Benzinga, Barchart, Kitco and Macrotrends.

“This new marketing campaign reflects how we have arrived at a pivotal point in our growth and development following a key acquisition, and a number of new products set for launch over the next several months,” commented Healthy Extracts president, Duke Pitts.

“All of this has coalesced to make it the ideal time to raise our corporate profile for the benefit of our customers, distribution partners and shareholders,” continued Pitts. “It is also one of several initiatives we are working on to raise awareness of our unique, clinically-proven natural products, and the enormous market opportunities and competitive advantages they create.”

Healthy Extracts’ heart-health products exclusively feature the world’s strongest Citrus Bergamot SuperFruit™ extract in North America. Backed by more than 17 published clinical trials, Citrus Bergamot SuperFruit has been shown to naturally reduce cholesterol, improve heart health and address metabolic syndrome. In 2020, the U.S. heart-health supplement market was $4.5 billion, according to a ResearchAndMarkets report, and is projected to grow to $24.8 billion by 2027.

The marketing campaign will also highlight Healthy Extracts’ patent protected Fuel4Thought® (F4T®) formulation. F4T comprises the naturally-derived nootropic ingredients used in its recently introduced UBN™ ACTIVATE™ product which have been clinically proven to increase key brain activity by as much as 46 percent.

More than 100 clinical studies have shown ACTIVATE dramatically improves human cognitive behavior and mental focus by activating areas of the brain primarily responsible for attention, memory, mood, and quick reaction times.

The result of more than 20 years of scientific research, the F4T formulation is naturally derived, and has zero sugar and caffeine. With only one scoop of ACTIVATE added to water, coffee, or a smoothie, its powerful brain activation benefits have been shown to last eight hours or more.

ACTIVATE addresses the rapidly expanding brain health supplements market, which is expected to grow at an 8 percent compounded annual growth rate (CAGR) to reach $13.4 billion by 2028. It also targets the faster growing niche market for nootropics, substances designed to improve memory, creativity and motivation. The nootropics market totaled $2.4 billion in 2020, and is projected to reach $6.3 billion by 2028, growing at a CAGR of nearly 13 percent.

The proprietary formulation for F4T is protected by multiple issued and pending patents. The formulation includes highly concentrated medium chain triglycerides, F4T MCT, which are derived from Healthy Extracts’ patented extraction process. F4T MCTs have been clinically shown to elevate the level of ketones in the brain—a major alternative energy source—up to 5 times within 60 to 90 minutes post-consumption.

The formulation also includes a proprietary blend of other key ingredients, including a naturally sourced nootropic spearmint extract that is clinically demonstrated to support mental focus during the day without disrupting sleep at night; a protective antioxidant found naturally in the body that helps the brain function optimally, and promotes better mood and sleep habits; and a unique natural marigold extract that is scientifically shown to block blue light and replenish lutein, which is critical for optimum eye health.

Learn more about UBN ACTIVATE or to order today at tryubn.com.

For more about the company’s heart-health products, go to bergametna.com.

For investor information, visit: healthyextractsinc.com.

About InvestingChannel
InvestingChannel is the most innovative and scalable marketing platform in financial media. Its deep industry expertise, proprietary technology and specialized services, uniquely surface and combine expert content and rich data for marketers, publishers, and financial audiences to engage and profit. To learn more, visit media.investingchannel.com.

About Healthy Extracts “Live Life Young Again”
Healthy Extracts Inc. is a platform for developing or acquiring science-forward, clinically proven, plant-based and proprietary products in select high-growth categories within the multibillion-dollar nutraceuticals market.

The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement containing Citrus Bergamot SuperFruit™. This superfruit is known to have the highest quality and concentration of polyphenols and flavonoids, and with healthy heart benefits backed by more 17 clinical studies.

UBN KETONOMICS® proprietary formulations have been clinically shown to improve brain health, including memory, cognition, focus and neuro-energy. UBN is pursuing intellectual property license opportunities for monetizing its IP portfolio of multiple issued and pending patents.

For more information visit: healthyextractsinc.combergametna.com or tryubn.com.

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Food and Drug Administration Disclosure

The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.

Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact

Investor & Media Contact
Ronald Both or Justin Lumley
CMA Investor & Media Relations
Tel (949) 432-7566
Email contact

 

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on July 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,600 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $13.34 per share, which is equal to the closing price of Spero’s common stock on The Nasdaq Global Select Market on July 30, 2021. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to each employee’s continued employment with Spero on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Spero Therapeutics Contacts:

Ted Jenkins, Vice President, Head of Investor Relations
Phone: +1 (617) 798-4039
Email: ir@sperotherapeutics.com

Ashley Robinson
LifeSci Advisors
Phone: +1 (617) 430-7577
Email: arr@lifesciadvisors.com

Media Contact: media@sperotherapeutics.com

Baudax Bio Announces Date of Reconvened Special Meeting

Baudax Bio Announces Date of Reconvened Special Meeting




Baudax Bio Announces Date of Reconvened Special Meeting

Special Meeting to be reconvened on August 11, 2021 solely with respect to Proposal 1

MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, recently announced that it has adjourned its Special Meeting of Shareholders (the “Special Meeting”) solely with respect to Proposal 1 set forth in its Definitive Proxy Statement (“Proxy Statement”) filed with the Securities and Exchange Commission on June 14, 2021. Proposal 1 is a proposal to amend the Company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Company had adjourned the Special Meeting with respect to Proposal 1 to provide its shareholders additional time to vote on Proposal 1. The Special Meeting will resume with respect to Proposal 1 at 9:00 a.m. Eastern time on August 11, 2021 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2021.

The record date for determining shareholders eligible to vote at the Special Meeting will remain the close of business on June 2, 2021. Shareholders who have already submitted a proxy do not need to vote again for the reconvened Special Meeting, as the proxies submitted will remain valid. Shareholders who have already submitted proxies and want to change their vote with respect to Proposal 1 can update their vote in the manner set forth in the Proxy Statement. Your vote will be recorded at the Special Meeting in accordance with your most recently submitted proxy.

Shareholders as of close of business on the June 2, 2021 record date who have not voted are encouraged to vote online at www.proxyvote.com or by telephone at 1-800-690-6903. Shareholders needing assistance voting or have questions may contact the Company’s proxy solicitation firm, Okapi Partners, at info@okapipartners.com or (855) 208-8902.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies. For more information, please visit www.baudaxbio.com.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this press release and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, among other things, risks related to the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO® or disruption in supply chain, Baudax Bio’s ability to maintain regulatory approval for ANJESO, Baudax Bio’s ability to successfully commercialize ANJESO; the acceptance of ANJESO by the medical community, including physicians, patients, health care providers and hospital formularies; Baudax Bio’s ability and that of Baudax Bio’s third party manufacturers to successfully scale-up the commercial manufacturing process for ANJESO, Baudax Bio’s ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO, Baudax Bio’s ability to raise future financing for continued product development, payment of milestones and ANJESO commercialization, Baudax Bio’s ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio’s ability to comply with the financial and other covenants under its credit facility, Baudax Bio’s ability to manage costs and execute on its operational and budget plans, the accuracy of Baudax Bio’s estimates of the potential market for ANJESO, Baudax Bio’s ability to achieve its financial goals; and Baudax Bio’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect Baudax Bio’s business and future results included in Baudax Bio’s filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

CONTACT:

Investor Relations Contact:
Argot Partners Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com

Lotus Reports Third Fiscal Quarter of 2021

Lotus Reports Third Fiscal Quarter of 2021




Lotus Reports Third Fiscal Quarter of 2021

VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) — Lotus Ventures Inc. (CSE: J) (OTC: LTTSF) (FRA: LV9) (“Lotus”, or the “Company”, or “Lotus Cannabis Co.”) a premium cannabis producer in Canada, today announced the results for the three and nine months ended May 31, 2021.

FINANCIAL HIGHLIGHTS

  • The Company reported quarterly revenue of $1.43 million and $4.24 million for the nine months ended May 31, 2021. The third quarter was also the fifth consecutive quarter where revenues continued to exceed $1.37 million.
  • Gross margin before fair value adjustments of $478,268, or 33% of net revenue for the three-month period. Gross margin after fair value adjustments of $616,083, or 42% of net revenue in the third quarter.
  • The Company reported its fourth profitable quarter and net income of $208,893 or 14% of net revenue for the three-month period.
  • The Company has now recorded positive EBITDA in four quarters since commencing operations.
  • The Company paid $415,765 of loans payable during the nine months ended May 31, 2021.

OPERATING HIGHLIGHTS

  • The Company increased harvest yields by approximately 15% and sold 626,000 grams in the third quarter. The Company cleared out a portion of small flower inventory at market prices which weighed on the average selling price in the quarter. The Kalifornia continues to obtain favorable wholesale selling prices when sold to the market.
  • The Company’s Kalifornia flower continues to test with consistent THC and terpene results. The Company’s flower is currently sold in six provincial cannabis retailers from B.C. to Nova Scotia and is sold at leading private cannabis retailers such as Spiritleaf, Fire and Flower and Canna Cabana.
  • The Company completed its 51st harvest since commencing operations, achieving craft quality at a commercial scale.

CORPORATE HIGHLIGHTS

  • The Company engaged Oak Hill Financial on May 25th, 2021 to enhance the Company’s capital market presence. Oak Hill has introduced the Company to new institutional investors and prospective lenders in preparation for the Phase 2 Expansion.

RESULTS OF OPERATIONS

Selected Quarterly Financial Data (unaudited)

The financial results of the Company for the five most recent quarters are summarized below:

Description Three months ended May 31, 2021 Three months ended Feb 28, 2021 Three months ended Nov 30, 2020 Three months ended Aug 31, 2020 Three months ended May 31, 2020
Revenues $1,437,763 $1,431,509 $1,376,270 $1,782,613 $1,775,878
Cost of Goods Sold $(959,495) $(741,533) $(616,880) $(683,159) $(807,079)
Gross Margin $478,268  $698,919 $848,566 $663,831 $1,671,649
Net Income (Loss) $208,893 $329,414 $(339,835) $(231,443) $1,231,779
Net Income (Loss) per Share, Basic and Diluted 0.00 0.00 $0.00 $0.00 $0.01
EBITDA $394,586 $514,122 $(149,427) $(36,129) $1,449,314
Total Assets $16,845,615 $16,841,875 $16,413,969 $16,908,437 $17,245,515
Total Long-Term Liabilities $Nil $Nil $Nil $Nil $Nil
Cash Dividends / Share $Nil $Nil $Nil $Nil $Nil

“This quarter was another step towards stabilizing our financial performance as we prepare to expand our facility, and our sales have been consistent throughout the first three quarters of this year,” said Dale McClanaghan, Lotus CEO.

The Company’s third quarter financial results are available on SEDAR or on the Company’s website at lotuscannabis.ca/investors. In addition, the Company has uploaded a new Investor Presentation to its website.

For investor inquiries please reach out to our Investor Relations.

ON BEHALF OF THE BOARD:
Lotus Ventures Inc.
“Dale McClanaghan”
Dale McClanaghan, President and CEO

About Lotus Ventures Inc.
Lotus Ventures Inc. is one of the largest independent premium-craft cannabis producers in Canada. The Company leverages its decades of experience in controlled-environment agriculture, construction and real estate development with the goal to be a low-cost producer of high-quality cannabis.

Our consumer brand Lotus Cannabis Co. ™ has achieved one of the top selling flower products in Ontario through a collaborative strain launch with Kolab Project, helping cultivate our reputation as a consistent and high-quality flower producer. The Company has established wholesale relationships across Canada and has its flower listed in eight provinces.

To invest in the Company, Lotus Ventures Inc. is listed on the Canadian Securities Exchange under the symbol “J”, on the OTC Markets under the symbol “LTTSF” and on the Frankfurt Stock Exchange under the symbol “LV9”.

For More Information:

President & CEO
Dale McClanaghan
dalemcclanaghan@gmail.com
604-644-9844 

Investor Relations
Daniel McRobert
investors@lotuscannabis.ca
604-842-4625

To learn more, visit lotuscannabis.ca or follow our Lotus Cannabis brand on social media.

Twitter: @lotuscannabisco, LinkedIn: @lotuscannabisco, Instagram: @lotuscannabiscoFacebook: @lotuscanna

Forward Looking Information:
The information contained within this news release has been prepared by Lotus Ventures Inc. This document includes certain statements that are not descriptions of historical facts but are forward-looking statements. Such statements include, among others, those concerning our expected financial performance and strategic and operational plans, our future operating results, our expectations regarding the market for medical and recreational cannabis products, our expectations regarding the continued growth of the medical and recreational cannabis market, as well as all assumptions, expectations, predictions, intentions, or beliefs about future events. Users are cautioned that any such forward-looking statements are not guarantees of future performance and that a number of risks and uncertainties could cause our actual results to differ materially from those anticipated, expressed or implied in the forward-looking statements. These risks and uncertainties have not been documented or mentioned in this document nor other communications made by the company. The words “believe,” “expect,” “anticipate,” “project,” “targets,” “optimistic,” “intend,” “aim,” “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law. All financial information contained within this news release has been recorded in Canadian dollars.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Zomedica Announces 2021 Annual Meeting Results

Zomedica Announces 2021 Annual Meeting Results




Zomedica Announces 2021 Annual Meeting Results

ANN ARBOR, Mich., July 30, 2021 (GLOBE NEWSWIRE) — Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2021 Annual Virtual-Only Meeting of Shareholders (the “Meeting”) held on July 30, 2021.

At the Meeting, the Company’s shareholders approved the items of business as follows:

  • Election of Jeffrey Rowe, Robert Cohen, Johnny D. Powers, Rodney Williams, Chris MacLeod and Christopher Wolfenberg as directors; and
  • Appointment of Grant Thornton LLP as the auditors of the Company and authorization of the board of directors of the Company to fix their remuneration.

Additional information regarding the voting on these matters will be filed separately by the Company on SEDAR (www.sedar.com) and EDGAR (www.sec.gov).

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Investor Relations Contact:
PCG Advisory
Kirin Smith, President
ksmith@pcgadvisory.com
+1 646.863.6519

 

Jushi Holdings Inc. Receives ~$14.4 Million Interim Arbitration Award

Jushi Holdings Inc. Receives ~$14.4 Million Interim Arbitration Award




Jushi Holdings Inc. Receives ~$14.4 Million Interim Arbitration Award

Arbitration Panel Rules in Favor of Jushi in a Breach of Contract and Breach of Implied Covenant of Good Faith Claims Against San Felasco Nurseries, Inc.

BOCA RATON, Fla., July 30, 2021 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that the American Arbitration Association (the “Panel”) awarded $14,364,920.10 (the “Interim Award”) to Jushi FL SPV, LLC (“Jushi FL”), a subsidiary of Jushi Holdings Inc., in its dispute against San Felasco Nurseries, Inc. (“San Felasco”), a subsidiary of Harvest Health & Recreation, Inc. (“Harvest”). The Interim Award consists of $10,637,012 in damages, plus $3,727,908.14 in pre-award interest (accrued at a rate of $3,497.099 per day) and post-award interest at a rate of 12% per annum. The Panel of three arbiters also affirmed that Jushi is entitled to recoup attorneys’ fees from San Felasco, in an amount to be determined by the Panel.

The Interim Award is based on breach of contract and breach of implied covenant of good faith claims brought by Jushi against San Felasco in October of 2018. In its order, the Panel found that San Felasco improperly terminated its franchise agreements with Jushi FL without cause and in bad faith. San Felasco then sold its Florida cannabis business to Harvest, depriving Jushi of the royalties it would otherwise have realized. Following a final hearing in May of 2021, the Panel issued the Interim Award on July 29, 2021.

“I am very pleased that the arbitration panel has ruled in our favor,” said Jim Cacioppo, Chief Executive Officer, Chairman and Founder of Jushi. “This is the right outcome and highlights the strength of our Company from a legal and business development perspective to successfully navigate through this complicated and highly regulated industry. We look forward to continuing to execute on our strategy to build the leading, vertically integrated operator by expanding our footprint and driving profitability in the markets where we currently operate.”

Jushi is represented by Wheeler Trigg O’Donnell LLP, in Denver. San Felasco is represented by Kasowitz Benson Torres LLP.

About Jushi Holdings Inc.
We are a vertically integrated cannabis company led by an industry leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts and competitive applications. Jushi strives to maximize shareholder value while delivering high quality products across all levels of the cannabis ecosystem. For more information please visit www.jushico.com or our social media channels, InstagramFacebookTwitter and LinkedIn.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, involve estimates, projections, plans, goals, forecasts, and assumptions that may prove to be inaccurate. As a result, actual results could differ materially from those expressed by such forward-looking statements and such statements should not be relied upon. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or may contain statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “will continue,” “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include but are not limited to, information concerning the expectations regarding Jushi, or the ability of Jushi to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has certain expectations and has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward- looking information and statements are the following: the ability of Jushi to successfully and/or timely achieve business objectives, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; and compliance with extensive government regulation, as well as other risks and uncertainties which are more fully described in the Company’s Management, Discussion and Analysis for the three months ended March 31, 2021, and other filings with securities and regulatory authorities which are available at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward- looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward- looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

Not for distribution to United States newswire services or for dissemination in the United States.

For further information, please contact:

Investor Relations
Michael Perlman
Executive Vice President of Investor Relations and Treasury
Investors@jushico.com
(561) 281-0247

Media Contact
Ellen Mellody
MATTIO Communications
Ellen@Mattio.com
(570) 209-2947

EssilorLuxottica : Publication of the 2021 Interim Financial Report

EssilorLuxottica : Publication of the 2021 Interim Financial Report




EssilorLuxottica : Publication of the 2021 Interim Financial Report

Publication of the 2021 Interim Financial Report

Charenton-le-Pont, France (July 30, 20216:30pm) – The Board of Directors of EssilorLuxottica met yesterday to approve the condensed consolidated interim financial statements for the six-month period ended June 30, 2021.

EssilorLuxottica’s 2021 Interim Financial Report has been published today.

In addition to the press release announcing H1 results, the Interim Financial Report comprises the condensed consolidated interim financial statements, the half year management report, the statement by the persons responsible for the Interim Financial Report and the auditors’ review report.

The Interim Financial Report can be downloaded from the Company’s website, https://www.essilorluxottica.com/, “Investors / Publications and Downloads” section, or by clicking on:
https://www.essilorluxottica.com/sites/default/files/documents/2021-07/2021.06_EN_INTERIM%20Financial%20Report_Final.pdf

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. Formed in 2018, its mission is to help people around the world to see more, be more and live life to its fullest by addressing their evolving vision needs and personal style aspirations. The Company brings together the complementary expertise of two industry pioneers, one in advanced lens technology and the other in the craftsmanship of iconic eyewear, to set new industry standards for vision care and the consumer experience around it. Influential eyewear brands including Ray-Ban and Oakley, lens technology brands including Varilux and Transitions, and world-class retail brands including Sunglass Hut and LensCrafters as well as – since 1 July 2021 via a 76.72% interest – GrandVision network are part of the EssilorLuxottica family. In 2020, EssilorLuxottica had over 140,000 employees and consolidated revenues of Euro 14.4 billion. The EssilorLuxottica share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESLX.PA; Bloomberg: EL:FP.

  

CONTACTS

Head of Investor Relations                                 Head of Corporate Communications
Giorgio Iannella                                             Marco Catalani
e-mail: ir@essilorluxottica.com                               e-mail: media@essilorluxottica.com

Attachment